[Proceedings of The National Academy of Sciences of The United States of America] Researchers compared the function of isolated pancreatic δ cells of cadaveric nondiabetic and T2D donors by single cell total internal reflection microscopy, electrophysiology, and secretion measurements.

[Redox Biology] Scientists identified cysteine as a key regulator of islet glucagon secretion through redox control of α-cell electrical excitability.

[Endocrinology] Investigators examined the effects of imeglimin, a novel antidiabetic agent, in normal glucose-tolerant C57BL/6 mice and isolated mouse islets using concentrations corresponding to clinically achieved plasma levels.

[Cancer Immunology Research] The authors reported that the RNA-binding protein human antigen R (HuR) is enriched in human PDAC and negatively correlates with T cell infiltration.

[Cancer Letters] Researchers conducted a saturation mutagenesis library screening of the full-length Kirsten rat sarcoma virus gene (KRAS)^G12D protein in a pancreatic cancer cell line carrying KRAS^G12D mutation to explore the drug resistance characteristics of KRAS^G12D-selective inhibitors.

[Diabetes] Using genetically engineered mouse models and matched organoids, scientists dissected complex-specific adaptive programs elicited by selective inactivation of mechanistic target of rapamycin (mTOR)C1 or mTORC2. Hyperactivation of mTORC1 and mTORC2 is common in PDAC.

[Oncogene] Investigators developed an copper-transporting ATPase 2 (ATP7B)-targeting autophagy-targeting chimera (AUTAC), the first autophagy-tethering compound specifically designed to target ATP7B.

[Translational Oncology] Researchers integrated bulk and single-cell transcriptomic datasets to characterize inflammation-associated metabolic programs in PDAC.

[npj Metabolic Health and Disease] The authors synthesize evidence from over 600 GWAS loci and the primary literature published between 2008 and 2026 to explain insulin secretion, insulin signaling, and diabetes susceptibility, converting GWAS associations into mechanistic insight and genotype-guided precision therapies.

[vTv Therapeutics, Inc.] vTv Therapeutics, Inc. announced that the first participant has been randomized in its Phase IIa Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use HCL insulin delivery systems.

[Swim Across America] Swim Across America has awarded a $450,000 research grant to Vanderbilt-Ingram Cancer Center to support a promising new approach to treating ovarian cancer which aims to prevent immune checkpoint failure.

[Progentos Therapeutics] Progentos Therapeutics announced that the first participant has been dosed in its Phase I/IIa clinical trial of PRO-1562, a small molecule designed to restore neurologic function in patients with Multiple Sclerosis, a chronic immune-mediated disease of the central nervous system.